Paris-based Sanofi (Nasdaq:SNY) is the fastest company to reduce insulin prices. The pharmaceutical behemoth said it would cut the list price of Lantus (insulin glargine injection) by 78%. Lantus is its most commonly prescribed insulin in the U.S. Moreover, Sanofi will implement a $35 cap on out-of-pocket expenses for users of the insulin. Sanofi has also…
The Biden administration vows to increase COVID-19 antiviral supplies
White House officials have a plan to ramp up the availability of Pfizer’s COVID-19 antiviral Paxlovid, according to a report from Bloomberg. White House Covid-19 Response Coordinator Dr. Ashish Jha said that the administration would announce more details about the plans to make Paxlovid more widely available in the coming week. The administration plans to launch…
Walmart teams up with Novo Nordisk to launch private-brand analog insulin
Walmart (NYSE:WMT) is launching what it describes as the first private label analog insulin. The company estimates the insulin products will save customers between 58% and 70% of the cost of branded insulin. Novo Nordisk (NYSE:NVO) will manufacture the analog insulin, which is a type of lab-grown insulin genetically engineered to optimize glucose control. The…
DOJ sues Walmart over its alleged role in opioid crisis
The Trump administration sued Walmart (NYSE: WMT), faulting the company for filling prescriptions from “pill-mill” physicians. The Justice Department lawsuit also alleges that Walmart attempted to maximize profits by understaffing pharmacies and emphasizing the quantity of prescriptions over quality control in its 5,000-plus retail locations across the U.S. The U.S. lawsuit also argues that Walmart lacks…